Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Roger J, Brüggemann"'
Autor:
Didi Bury, Corline E.J. Parmentier, Wim J.E. Tissing, Rob Pieters, Louis J. Bont, Roger J. Brüggemann, Tom F.W. Wolfs
Publikováno v:
EJC Paediatric Oncology, Vol 3, Iss , Pp 100143- (2024)
Background: Childhood acute lymphoblastic leukaemia (ALL) cure rates have improved, but invasive mould disease (IMD) remains a life-threatening complication. Here, we evaluate the epidemiology, clinical presentation, treatment and outcome of IMD in p
Externí odkaz:
https://doaj.org/article/5bc0c005081d4b1286e1488144ede9b5
Autor:
Intan M.W. Dewi, Cristina Cunha, Martin Jaeger, Mark S. Gresnigt, Marina E. Gkountzinopoulou, Fadel M. Garishah, Cláudio Duarte-Oliveira, Cláudia F. Campos, Lore Vanderbeke, Agustin Resendiz Sharpe, Roger J. Brüggemann, Paul E. Verweij, Katrien Lagrou, Greetje Vande Velde, Quirijn de Mast, Leo A.B. Joosten, Mihai G. Netea, Andre J.A.M. van der Ven, Joost Wauters, Agostinho Carvalho, Frank L. van de Veerdonk
Publikováno v:
Cell Reports Medicine, Vol 2, Iss 5, Pp 100289- (2021)
Summary: Influenza-associated pulmonary aspergillosis (IAPA) has been reported increasingly since the advent of use of neuraminidase (NA) inhibitors following the 2009 influenza pandemic. We hypothesize that blocking host NA modulates the immune resp
Externí odkaz:
https://doaj.org/article/6db0b061daa24bc6ab6079fafd1b44cf
Autor:
Jason A. Roberts, Fekade Sime, Jeffrey Lipman, Maria Patricia Hernández-Mitre, João Pedro Baptista, Roger J. Brüggemann, Jai Darvall, Jan J. De Waele, George Dimopoulos, Jean-Yves Lefrant, Mohd Basri Mat Nor, Jordi Rello, Leonardo Seoane, Monica A. Slavin, Miia Valkonen, Mario Venditti, Wai Tat Wong, Markus Zeitlinger, Claire Roger
Publikováno v:
Critical Care and Resuscitation. 25:1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f7441c9ff4221aff6032a7c8f8e9631
https://doi.org/10.1016/j.ccrj.2023.04.002
https://doi.org/10.1016/j.ccrj.2023.04.002
Autor:
Frank L van de Veerdonk, Mihai G Netea, Marcel van Deuren, Jos WM van der Meer, Quirijn de Mast, Roger J Brüggemann, Hans van der Hoeven
Publikováno v:
eLife, Vol 9 (2020)
COVID-19 patients can present with pulmonary edema early in disease. We propose that this is due to a local vascular problem because of activation of bradykinin 1 receptor (B1R) and B2R on endothelial cells in the lungs. SARS-CoV-2 enters the cell vi
Externí odkaz:
https://doaj.org/article/99e8b232f30449d9afb07f4f518d0e61
Publikováno v:
Journal of Fungi, Vol 8, Iss 1, p 18 (2021)
Invasive fungal infections (IFI) are a common infection-related cause of death in immunocompromised patients. Approximately 10 million people are at risk of developing invasive aspergillosis annually. Detailed study of the pharmacokinetics (PK) and p
Externí odkaz:
https://doaj.org/article/52e90e94037844df8583b8a5ea2e2759
Autor:
Ruth Van Daele, Joost Wauters, Pieter De Cock, Franky Buyle, John Leys, Pieter Van Brantegem, Matthias Gijsen, Pieter Annaert, Yves Debaveye, Katrien Lagrou, Willy E. Peetermans, Roger J. Brüggemann, Isabel Spriet
Publikováno v:
Antibiotics, Vol 10, Iss 9, p 1112 (2021)
Background: Voriconazole is an antifungal drug used as one of the first-line treatments for invasive aspergillosis. This drug is extensively metabolized, predominantly via cytochrome P450 enzymes. An interaction between flucloxacillin and voriconazol
Externí odkaz:
https://doaj.org/article/d518ce7c695b4b679e9787766d2dad50
Autor:
Ruth Van Daele, Joost Wauters, Katrien Lagrou, Raphaël Denooz, Marie-Pierre Hayette, Matthias Gijsen, Roger J. Brüggemann, Yves Debaveye, Isabel Spriet
Publikováno v:
Microorganisms, Vol 9, Iss 10, p 2068 (2021)
Background: Fluconazole is one of the oldest antifungal drugs. Previous studies have raised concerns considering variability in exposure and inadequate target attainment in critically ill patients. The current study aims to define variability and tar
Externí odkaz:
https://doaj.org/article/555544e255df4869b0a45eb0144d8735
Autor:
Lu Chen, Koen P van Rhee, Roeland E Wasmann, Elke H J Krekels, Marinus J Wiezer, Eric P A van Dongen, Paul E Verweij, Paul D van der Linden, Roger J Brüggemann, Catherijne A J Knibbe
Publikováno v:
Journal of Antimicrobial Chemotherapy, 77, 8, pp. 2217-2226
Journal of Antimicrobial Chemotherapy, 77(8), 2217-2226. OXFORD UNIV PRESS
Journal of Antimicrobial Chemotherapy, 77, 2217-2226
Journal of Antimicrobial Chemotherapy, 77(8), 2217-2226. OXFORD UNIV PRESS
Journal of Antimicrobial Chemotherapy, 77, 2217-2226
Background Fluconazole is commonly used to treat or prevent fungal infections. It is typically used orally but in critical situations, IV administration is needed. Obesity may influence the pharmacokinetics and therapeutic efficacy of a drug. In this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e5e40ef5eaa15ad1ed00abbbef8b1c
https://doi.org/10.1093/jac/dkac160
https://doi.org/10.1093/jac/dkac160
Publikováno v:
Drugs, 83, 75-86
Drugs, 83, 1, pp. 75-86
Drugs, 83, 1, pp. 75-86
Contains fulltext : 290608.pdf (Publisher’s version ) (Closed access) BACKGROUND: Posaconazole is widely used for the prophylaxis and treatment of invasive fungal diseases. Because of the limited and variable absorption of the initially available o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ee3f88a2caea6de411f3b3e8deb99e8
http://hdl.handle.net/2066/290608
http://hdl.handle.net/2066/290608
Publikováno v:
Drugs.
Posaconazole is widely used for the prophylaxis and treatment of invasive fungal diseases. Because of the limited and variable absorption of the initially available oral suspension, a delayed-release tablet and intravenous formulation were developed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4797eeafd8a5bcec7af082af664e1073
https://pubmed.ncbi.nlm.nih.gov/36607589
https://pubmed.ncbi.nlm.nih.gov/36607589